CompletedNot Applicable

Donor-derived Cell-free DNA in Kidney Transplant Recipients

Czechia143 participantsStarted 2021-10-21

Plain-language summary

Donor-derived cell-free DNA (dd-cfDNA) is a promising non-invasive biomarker of kidney allograft rejection. In this prospective, single center, observational monitoring study, we aim to evaluate a role of dd-cfDNA in predicting kidney allograft injuries, i.e. rejection and non-rejection injuries within 12 months, and to monitor the effect of anti rejection treatment.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Recipient age ≥ 18 years and \<85 years * Written Informed Consent cohort 1 * deceased donor kidney transplant recipient cohort 2 * patients with kidney allograft biopsy at center showing any type of rejection which is going to be treated * patient wishing to repeatedly travel to center Exclusion Criteria: cohort 1 * living donor * multiple transplant * dual transplant * haematopoetic stem cell transplant in a history

What they're measuring

dd-cfDNA

Timeframe: 12 months

dd-cfDNA

Timeframe: 4 weeks

Trial details

NCT IDNCT06476717

SponsorInstitute for Clinical and Experimental Medicine

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2024-05-12

View on ClinicalTrials.gov More Kidney Transplantation trials